Oxford Biomedica PLC John Dawson to retire from Oxford Biomedica (5600Y)
January 17 2022 - 1:01AM
UK Regulatory
TIDMOXB
RNS Number : 5600Y
Oxford Biomedica PLC
17 January 2022
John Dawson to retire from Oxford Biomedica
Oxford, UK - 17 January 2022: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Group" or "the Company") a leading gene
and cell therapy company, today announces that, after more than 13
years of service, John Dawson, Chief Executive Officer, has
signalled to the Board his intention to retire from the Company.
Accordingly, the Board has initiated a formal search for a
successor.
Dr. Roch Doliveux, Chairman of Oxford Biomedica, commented:
"John has provided more than 13 years of dedicated service and
leadership to Oxford Biomedica and, on behalf of the Board and all
of our staff, we thank him wholeheartedly. His successful career
with the Company was underlined very recently by a much-deserved
CBE awarded for services to UK Life Science. Under his leadership,
together with the strong senior executive team, Oxford Biomedica
has grown into an industry leader in lentiviral vectors, delivered
multiple partnerships and successfully manufactured life-saving
COVID-19 vaccine, all due to the expertise and robustness of the
Company's management team. We have commenced a formal process to
appoint a successor who will lead the Group through its next phase
of growth whilst also ensuring the Company remains fully focussed
on the execution of its strategy of delivering life changing gene
therapies to patients."
John Dawson, Chief Executive Officer of Oxford Biomedica, added:
" I am immensely proud of Oxford Biomedica's achievements, and will
retire at the appropriate time. Oxford Biomedica is now a global
market leader in viral vector technologies for gene and cell
therapy. The world-class management team at Oxford Biomedica is
surrounded by a dedicated workforce of over 740 people who have
demonstrated a unique robustness and ability to deliver --
exemplified several times over the recent years and certainly by
our contribution to the fight against the pandemic. I believe this
is the right time to start the transition to a new leader given the
robustness of the senior team and Company as a whole, which is
undoubtedly stronger than ever before."
-Ends-
Enquiries:
Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com
John Dawson, Chief Executive Officer
Stuart Paynter, Chief Financial Officer
Sophia Bolhassan, Head of Investor Relations
Consilium Strategic Communications: T: +44 (0)20 3709 5700
Mary-Jane Elliott / Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVectorÂ(R)), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, CNS disorders and liver diseases. The Group has also
entered into a number of partnerships, including with Novartis,
Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics,
Santen, Beam Therapeutics, Boehringer Ingelheim, Arcellx and
Cabaletta Bio, through which it has long-term economic interests in
other potential gene and cell therapy products. Additionally, the
Group has signed a 3-year master supply and development agreement
with AstraZeneca for large-scale manufacturing of the adenoviral
based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is
based across several locations in Oxfordshire, UK and employs more
than 740 people. Further information is available at
www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAFFFILLAIRLIF
(END) Dow Jones Newswires
January 17, 2022 02:01 ET (07:01 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024